GLIDIMIN-MV2

A triple fixed dose combination of metformin, glimepiride, and voglibose could be a better choice in Indians as the combination is safe, affordable and effective in attaining optimal glucose levels and reducing the complications

Glimepiride is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sulfonylurea class of drugs.

Metformin is often used as monotherapy or in combination when diet and exercise are not effective at lowering hyperglycemia. According to the American Diabetes Association (ADA), metformin is the preferred first-line agent in patients with type-2 diabetes mellitus in adults and children ten years and older.

Voglibose is a therapeutic drug used to lower blood glucose levels after consuming food in people suffering from Type 2 diabetes, Diabetes Mellitus.It is an alpa-glucosidase inhibitor. Sugar absorption is delayed as voglibose regulates the intestinal enzymes from breaking down complex carbs to simpler carbs such as glucose.

Composition:

Each uncoated bilayered tablet contains:

Glimepiride IP 2mg

Voglibose 0.3mg

Metformin Hydrochloride IP (as ER) 500mg

Mechanism:

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates.In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level.

The anti-hypoglycaemic action of voglibose results from a reversible inhibition of membrane bound intestines α glycosidase hydrolize enzymes which hydrolize oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine.